Literature DB >> 19118022

Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts.

Charlotte Anderberg1, Hong Li, Linda Fredriksson, Johanna Andrae, Christer Betsholtz, Xuri Li, Ulf Eriksson, Kristian Pietras.   

Abstract

Cancer results from the concerted performance of malignant cells and stromal cells. Cell types populating the microenvironment are enlisted by the tumor to secrete a host of growth-promoting cues, thus upholding tumor initiation and progression. Platelet-derived growth factors (PDGF) support the formation of a prominent tumor stromal compartment by as of yet unidentified molecular effectors. Whereas PDGF-CC induces fibroblast reactivity and fibrosis in a range of tissues, little is known about the function of PDGF-CC in shaping the tumor-stroma interplay. Herein, we present evidence for a paracrine signaling network involving PDGF-CC and PDGF receptor-alpha in malignant melanoma. Expression of PDGFC in a mouse model accelerated tumor growth through recruitment and activation of different subsets of cancer-associated fibroblasts. In seeking the molecular identity of the supporting factors provided by cancer-associated fibroblasts, we made use of antibody arrays and an in vivo coinjection model to identify osteopontin as the effector of the augmented tumor growth induced by PDGF-CC. In conclusion, we establish paracrine signaling by PDGF-CC as a potential drug target to reduce stromal support in malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118022      PMCID: PMC2613547          DOI: 10.1158/0008-5472.CAN-08-2724

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  PDGF receptors as cancer drug targets.

Authors:  Kristian Pietras; Tobias Sjöblom; Kristofer Rubin; Carl-Henrik Heldin; Arne Ostman
Journal:  Cancer Cell       Date:  2003-05       Impact factor: 31.743

2.  PDGF-D is a potent transforming and angiogenic growth factor.

Authors:  Hong Li; Linda Fredriksson; Xuri Li; Ulf Eriksson
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

Review 3.  Reactive stroma in prostate cancer progression.

Authors:  J A Tuxhorn; G E Ayala; D R Rowley
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

4.  Human breast carcinoma desmoplasia is PDGF initiated.

Authors:  Z M Shao; M Nguyen; S H Barsky
Journal:  Oncogene       Date:  2000-09-07       Impact factor: 9.867

5.  Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis.

Authors:  F Moinfar; Y G Man; L Arnould; G L Bratthauer; M Ratschek; F A Tavassoli
Journal:  Cancer Res       Date:  2000-05-01       Impact factor: 12.701

6.  Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis.

Authors:  Daria Leali; Patrizia Dell'Era; Helena Stabile; Barbara Sennino; Ann F Chambers; Antonella Naldini; Silvano Sozzani; Beatrice Nico; Domenico Ribatti; Marco Presta
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy.

Authors:  Annica Pontén; Xuri Li; Peter Thorén; Karin Aase; Tobias Sjöblom; Arne Ostman; Ulf Eriksson
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

8.  Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms.

Authors:  T Guy Hamilton; Richard A Klinghoffer; Philip D Corrin; Philippe Soriano
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

9.  Systemic endocrine instigation of indolent tumor growth requires osteopontin.

Authors:  Sandra S McAllister; Ann M Gifford; Ashley L Greiner; Stephen P Kelleher; Matthew P Saelzler; Tan A Ince; Ferenc Reinhardt; Lyndsay N Harris; Bonnie L Hylander; Elizabeth A Repasky; Robert A Weinberg
Journal:  Cell       Date:  2008-06-13       Impact factor: 41.582

Review 10.  The complexities of breast cancer desmoplasia.

Authors:  R A Walker
Journal:  Breast Cancer Res       Date:  2001-02-01       Impact factor: 6.466

View more
  93 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

Review 2.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

3.  PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets.

Authors:  Xu Hou; Anil Kumar; Chunsik Lee; Bin Wang; Pachiappan Arjunan; Lijin Dong; Arvydas Maminishkis; Zhongshu Tang; Yang Li; Fan Zhang; Shi-Zhuang Zhang; Piotr Wardega; Sagarika Chakrabarty; Baoying Liu; Zhijian Wu; Peter Colosi; Robert N Fariss; Johan Lennartsson; Robert Nussenblatt; J Silvio Gutkind; Yihai Cao; Xuri Li
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

4.  Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer.

Authors:  Farhad Kosari; John C Cheville; Cristiane M Ida; R Jeffrey Karnes; Alexey A Leontovich; Thomas J Sebo; Sibel Erdogan; Erika Rodriguez; Stephen J Murphy; George Vasmatzis
Journal:  Am J Pathol       Date:  2012-05-26       Impact factor: 4.307

5.  PDGF-D promotes dermal fibroblast invasion in 3-dimensional extracellular matrix via Snail-mediated MT1-MMP upregulation.

Authors:  Zhuo Qin; Jinfa Feng; Yusi Liu; Li-Li Deng; Changlian Lu
Journal:  Tumour Biol       Date:  2015-08-04

Review 6.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

7.  Tumor-α9β1 integrin-mediated signaling induces breast cancer growth and lymphatic metastasis via the recruitment of cancer-associated fibroblasts.

Authors:  Daichi Ota; Masashi Kanayama; Yutaka Matsui; Koyu Ito; Naoyoshi Maeda; Goro Kutomi; Koichi Hirata; Toshihiko Torigoe; Noriyuki Sato; Akinori Takaoka; Ann F Chambers; Junko Morimoto; Toshimitsu Uede
Journal:  J Mol Med (Berl)       Date:  2014-08-08       Impact factor: 4.599

8.  Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects.

Authors:  Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

9.  An oncogenic activity of PDGF-C and its splice variant in human breast cancer.

Authors:  Alyssa Bottrell; Yong Hong Meng; Abdo J Najy; Newton Hurst; Seongho Kim; Chong Jai Kim; Eun-Sook Kim; Aree Moon; Eun Joo Kim; So Yeon Park; Hyeong-Reh Choi Kim
Journal:  Growth Factors       Date:  2019-09-23       Impact factor: 2.511

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.